Bristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO says
October 05, 2020 at 20:28 PM EDT
"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.
